Phenotypes Associated with This Genotype

Genotype
MGI:5581956

• Allelic Composition: Ctnnb1^tm1Mmt/Ctnnb1⁺; Pparg^{tm1.1(tTA)Jmgr}/Pparg⁺; Tg(tetO-cre)1Jaw/0
• Genetic Background: involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

skeleton

skeleton phenotype ( J:178340 )

N • doxycycline-treated mice exhibit normal bone formation and numbers of osteoblasts

abnormal osteoclast differentiation ( J:178340 )

• impaired in doxycycline-treated mice

decreased osteoclast cell number ( J:178340 )

• in doxycycline-treated mice

increased bone volume ( J:178340 )

• as early as P15 in doxycycline-treated mice

• 27-fold from 10 months of age in doxycycline-treated mice

increased compact bone volume ( J:178340 )

• in doxycycline-treated mice

abnormal trabecular bone morphology ( J:178340 )

• 4.6-fold increase in trabecular bone surface and a smaller bone surface to bone volume in doxycycline-treated mice

increased trabecular bone volume ( J:178340 )

• trabecular, cortical and total volume as early as P15 in doxycycline-treated mice

increased bone trabecula number ( J:178340 )

• 3.6-fold with reduced trabecular separation in doxycycline-treated mice

increased trabecular bone thickness ( J:178340 )

• 8.5-fold in doxycycline-treated mice

osteopetrosis ( J:178340 )

• severe in doxycycline-treated mice

• in mice following adult onset activation with doxycycline

decreased bone resorption ( J:178340 )

• in doxycycline-treated mice

hematopoietic system

abnormal osteoclast differentiation ( J:178340 )

• impaired in doxycycline-treated mice

extramedullary hematopoiesis ( J:178340 )

• in doxycycline-treated mice

decreased bone marrow cell number ( J:178340 )

• at 4 months in doxycycline-treated mice

absent bone marrow cell ( J:178340 )

• at 10 months in doxycycline-treated mice

decreased osteoclast cell number ( J:178340 )

• in doxycycline-treated mice

increased splenocyte number ( J:178340 )

• gradual in doxycycline-treated mice

cellular

abnormal osteoclast differentiation ( J:178340 )

• impaired in doxycycline-treated mice

immune system

abnormal osteoclast differentiation ( J:178340 )

• impaired in doxycycline-treated mice

decreased osteoclast cell number ( J:178340 )

• in doxycycline-treated mice

increased splenocyte number ( J:178340 )

• gradual in doxycycline-treated mice